Please wait a minute...
Frontiers of Materials Science

ISSN 2095-025X

ISSN 2095-0268(Online)

CN 11-5985/TB

邮发代号 80-974

2019 Impact Factor: 1.747

Frontiers of Materials Science  2014, Vol. 8 Issue (4): 363-372   https://doi.org/10.1007/s11706-014-0262-8
  本期目录
Glucose-conjugated chitosan nanoparticles for targeted drug delivery and their specific interaction with tumor cells
Jing LI1,*(),Fang-Kui MA2,Qi-Feng DANG3,Xing-Guo LIANG1,Xi-Guang CHEN3,*()
1. College of Food Science and Engineering, Ocean University of China, Qingdao 266003, China
2. Freshwater Fisheries Research Institute of Shandong Province, Jinan 250013, China
3. College of Marine Life Science, Ocean University of China, Qingdao 266003, China
 全文: PDF(516 KB)   HTML
Abstract

A novel targeted drug delivery system, glucose-conjugated chitosan nanoparticles (GCNPs), was developed for specific recognition and interaction with glucose transporters (Gluts) over-expressed by tumor cells. GC was synthesized by using succinic acid as a linker between glucosamine and chitosan (CS), and successful synthesis was confirmed by NMR and elemental analysis. GCNPs were prepared by ionic crosslinking method, and characterized in terms of morphology, size, and zeta potential. The optimally prepared nanoparticles showed spherical shapes with an average particle size of (187.9±3.8) nm and a zeta potential of (-15.43±0.31) mV. The GCNPs showed negligible cytotoxicity to mouse embryo fibroblast and 4T1 cells. Doxorubicin (DOX) could be efficiently entrapped into GCNPs, with a loading capacity and encapsulation efficiency of 20.11% and 64.81%, respectively. DOX-loaded nanoparticles exhibited sustained-release behavior in phosphate buffered saline (pH 7.4). In vitro cellular uptake studies showed that the GCNPs had better endocytosis ability than CSNPs, and the antitumor activity of DOX/GCNPs was 4–5 times effectiveness in 4T1 cell killing than that of DOX/CSNPs. All the results demonstrate that nanoparticles decorated with glucose have specific interactions with cancer cells via the recognition between glucose and Gluts. Therefore, Gluts-targeted GCNPs may be promising delivery agents in cancer therapies.

Key wordsdrug delivery    target    nanoparticle    glucose transporter (Glut)    chitosan (CS)
收稿日期: 2014-06-13      出版日期: 2014-12-04
Corresponding Author(s): Jing LI   
 引用本文:   
. [J]. Frontiers of Materials Science, 2014, 8(4): 363-372.
Jing LI,Fang-Kui MA,Qi-Feng DANG,Xing-Guo LIANG,Xi-Guang CHEN. Glucose-conjugated chitosan nanoparticles for targeted drug delivery and their specific interaction with tumor cells. Front. Mater. Sci., 2014, 8(4): 363-372.
 链接本文:  
https://academic.hep.com.cn/foms/CN/10.1007/s11706-014-0262-8
https://academic.hep.com.cn/foms/CN/Y2014/V8/I4/363
Fig.1  
Sample Yield /% Ra) Content of NH2 /% DS /%
CS 5.49±0.05 79.90±0.03
GC 81 5.77±0.03 43.58±0.02 36.31±0.02
Tab.1  
Fig.2  
Sample ID Volume ratio (CS:CMCS) Zeta potential /mV Particle size /nm PdI
GCNPs-1 1:1 -7.13±0.55 1711.7±44.8 0.95±0.07
GCNPs-2 0.9:1 -12.73±0.35 427.7±5.9 0.40±0.01
GCNPs-3 0.8:1 -15.17±0.31 313.8±5.7 0.20±0.01
GCNPs-4 0.7:1 -15.43±0.31 187.9±3.8 0.13±0.01
GCNPs-5 0.6:1 -16.10±0.30 205.1±4.9 0.14±0.01
Tab.2  
Fig.3  
Fig.4  
Fig.5  
Fig.6  
Fig.7  
1 Chen C, Yu C H, Cheng Y C, . Biodegradable nanoparticles of amphiphilic triblock copolymers based on poly(3-hydroxybutyrate) and poly(ethylene glycol) as drug carriers. Biomaterials, 2006, 27(27): 4804–4814
2 Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic Oncology, 2008, 26(1): 57–64
3 Malam Y, Loizidou M, Seifalian A M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in Pharmacological Sciences, 2009, 30(11): 592–599
4 Byrne J D, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews, 2008, 60(15): 1615–1626
5 Sudimack J, Lee R J. Targeted drug delivery via the folate receptor. Advanced Drug Delivery Reviews, 2000, 41(2): 147–162
6 Hruz P W, Mueckler M M. Structural analysis of the GLUT1 facilitative glucose transporter. Molecular Membrane Biology, 2001, 18(3): 183–193
7 Olson A L, Pessin J E. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annual Review of Nutrition, 1996, 16(1): 235–256
8 Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. The Journal of General Physiology, 1927, 8(6): 519–530
9 Cullinane C, Solomon B, Hicks R J. Imaging of molecular target modulation in oncology: challenges of early clinical trials. Clinical and Translational Imaging, 2014, 2(1): 5–12
10 Liu D Z, Sinchaikul S, Reddy P V G, . Synthesis of 2′-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells. Bioorganic & Medicinal Chemistry Letters, 2007, 17(3): 617–620
11 Airley R, Evans A, Mobasheri A, . Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. Annals of Anatomy, 2010, 192(3): 133–138
12 Jó?wiak P, Lipińska A. The role of glucose transporter 1 (GLUT1) in the diagnosis and therapy of tumors. Post?py Higieny i Medycyny Do?wiadczalnej, 2012, 66: 165–174 (in Polish)
13 Ravi Kumar M N V. A review of chitin and chitosan applications. Reactive and Functional Polymers, 2000, 46(1): 1–27
14 Li J, Kong M, Cheng X J, . A facile method for preparing biodegradable chitosan derivatives with low grafting degree of poly(lactic acid). International Journal of Biological Macromolecules, 2011, 49(5): 1016–1021
15 Yang K, Gao T, Bao Z, . Preparation and characterization of a novel thermosensitive nanoparticle for drug delivery in combined hyperthermia and chemotherapy. Journal of Materials Chemistry B, 2013, 1(46): 6442–6448
16 Li P, Wang Y, Zeng F, . Synthesis and characterization of folate conjugated chitosan and cellular uptake of its nanoparticles in HT-29 cells. Carbohydrate Research, 2011, 346(6): 801–806
17 Chen X G, Li J, Cheng X J, . Process for preparing compounds of chitosan saccharified with aminosugar. US Patent, 8 202 971 B2, 2012-06-<day>19</day>
18 Hansen M B, Nielsen S E, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Journal of Immunological Methods, 1989, 119(2): 203–210
19 Dong Y, Feng S S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials, 2004, 25(14): 2843–2849
20 Wang H, Zhao P, Su W, . PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials, 2010, 31(33): 8741–8748
21 Li J, Kong M, Cheng X J, . Preparation of biocompatible chitosan grafted poly(lactic acid) nanoparticles. International Journal of Biological Macromolecules, 2012, 51(3): 221–227
22 Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 2010, 148(2): 135–146
23 Yoo J W, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: Temporal control over carrier properties to facilitate drug delivery. Advanced Drug Delivery Reviews, 2011, 63(14–15): 1247–1256
24 Hashida M, Takemura S, Nishikawa M, . Targeted delivery of plasmid DNA complexed with galactosylated poly(L-lysine). Journal of Controlled Release, 1998, 53(1–3): 301–310
25 Peer D, Karp J M, Hong S, . Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007, 2(12): 751–760
26 Choucair A, Soo P L, Eisenberg A. Active loading and tunable release of doxorubicin from block copolymer vesicles. Langmuir, 2005, 21(20): 9308–9313
27 Xun W, Wang H Y, Li Z Y, . Self-assembled micelles of novel graft amphiphilic copolymers for drug controlled release. Colloids and Surfaces B: Biointerfaces, 2011, 85(1): 86–91
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed